Previous post
Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”
Next post
By Setting Standards, Experts Aim to Tame a Wild West of AD Blood Tests